Metformin and lipopolysaccharide regulate transcription of NFATc2 gene via the transcription factor RUNX2.
10.12122/j.issn.1673-4254.2022.03.16
- Author:
Xiao Yang XUE
1
;
Zhong Hao LI
2
;
Ming ZHAO
2
Author Information
1. Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
2. Key Lab of Medical Shock and Microcirculation Research of Guangdong Province, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
NFATc2;
RUNX2;
lipopolysaccharide;
metformin;
reporter gene
- MeSH:
Core Binding Factor Alpha 1 Subunit/genetics*;
Humans;
Lipopolysaccharides/pharmacology*;
Luciferases/genetics*;
Metformin/pharmacology*;
NFATC Transcription Factors/genetics*;
Promoter Regions, Genetic;
T-Lymphocytes;
Transcription, Genetic/drug effects*;
Transfection
- From:
Journal of Southern Medical University
2022;42(3):425-431
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To construct a luciferase reporter gene vector carrying human nuclear factor of activated T cells 2 (NFATc2) gene promoter and examine the effects of metformin and lipopolysaccharide (LPS) on the transcriptional activity of NFATc2 gene.
METHODS:The promoter sequence of human NFATc2 gene was acquired from UCSC website for PCR amplification. NFATc2 promoter fragment was inserted into pGL3-basic plasmid double cleaved with Kpn Ⅰ and Hind Ⅲ. The resultant recombinant plasmid pGL3-NFATC2-promoter was co-transfected with the internal reference plasmid pRL-TK in 293F cells, and luciferase activity in the cells was detected. Reporter gene vectors of human NFATc2 gene promoter with different fragment lengths were also constructed and assayed for luciferase activity. The changes in transcription activity of NFATc2 gene were assessed after treatment with different concentrations of metformin and LPS for 24 h. We also examined the effect of mutation in RUNX2-binding site in NFATC2 gene promoter on the regulatory effects of metformin and LPS on NFATc2 transcription.
RESULTS:We successfully constructed pGL3-NFATc2-promoter plasmids carrying different lengths (2170 bp, 2077 bp, 1802 bp, 1651 bp, 1083 bp, 323 bp) of NFATc2 promoter sequences as verified by enzymatic digestion and sequencing. Transfection of 293F cells with the plasmid carrying a 1651 bp NFATc2 promoter (pGL3-1651 bp) resulted in the highest transcriptional activity of NFATc2 gene, and the luciferase activity was approximately 3.3 times that of pGL3-2170 bp (1.843 ± 0.146 vs 0.547 ± 0.085). Moderate (5 mmol/L) and high (10 mmol/L) concentrations of metformin significantly upregulated the transcriptional activity of pGL3-1651 bp by up to 2.5 and 3 folds, respectively. LPS at different doses also upregulated the transcriptional activity of pGL3-1651 bp by at least 1.6 folds. The mutation in the RUNX2 binding site on pGL3-1651 bp obviously reduced metformin- and LPS-induced enhancement of pGL3-1651bp transcription by 1.7 and 2 folds, respectively.
CONCLUSION:pGL3-NFATc2-promoter can be transcribed and activated in 293F cells, and LPS and metformin can activate the transcription of pGL3- NFATc2-promoter in a RUNX2-dependent manner.
